Unmet Needs in the Pathogenesis, Treatment of Systemic Lupus Erythematosus

Improved survival has ushered in new challenges that inadvertently increase the risk for death in patients with SLE.

Cardiovascular Disease Risk in Patients With Systemic Lupus Erythematosus

Improved treatment in SLE with increased life expectancy has been accompanied by an elevated risk for developing cardiovascular diseases.

Drug-Induced Lupus Erythematosus: Clinical Presentation and Differential Diagnosis

Drug-induced lupus erythematosus refers to an idiosyncratic side effect of medications with clinical features similar to the autoimmune-driven idiopathic lupus erythematosus.

Advancing Understanding of Shrinking Lung Syndrome in SLE

The diagnosis and management of shrinking lung syndrome, a rare complication of systemic lupus erythematosus, is discussed in a comprehensive review.

Optimal ANA Cutoff Titer as Entry Criterion for SLE Classification

The new approach in development proposes the use of positive indirect immunofluorescence ANA (IIF-ANA) as an entry criterion for SLE classification.

Lymphoma in Patients With Systemic Lupus Erythematosus: Expert Insights

In this expert interview, Sasha Bernatsky, MD, PhD, and Michelle Petri, MD, MPH, discuss the risk of non-Hodgkin lymphoma in SLE.

Lupus: Using Diet and Nutrition to Improve Symptoms and Outcomes

Consuming adequate amounts of the right nutrients, and limiting others, can help relieve symptoms and improve outcomes in patients with systemic lupus erythematosus.

Applying Precision Medicine to Systemic Lupus Erythematosus

Clinicians and researchers weigh in on the advent of precision medicine for the treatment of SLE.

EULAR Updates Recommendations for Reproductive Planning in SLE

Multidisciplinary experts provide 12 recommendations for the planning and management of pregnancy in systemic lupus erythematosus and/or antiphospholipid syndrome.

Case Study and Clinical Highlight: Respiratory Failure in a Patient With SLE

A female patient with systemic lupus erythematosus presents to the emergency department with an 8 week history of dyspnea, dysphonia, and non-productive cough.

Latest News

Active Nephritis in Active SLE: Identification of a New Biomarker

Active Nephritis in Active SLE: Identification of a New Biomarker

Anti-ficolin-2 autoantibodies may represent a biomarker for renal manifestations in patients with active systemic lupus erythematosus.

EULAR/ACR Systemic Lupus Erythematosus Classification Criteria Update

EULAR/ACR Systemic Lupus Erythematosus Classification Criteria Update

EULAR and ACR jointly funded and collaborated on creating a set of criteria that can be used to more accurately identify patients with SLE for inclusion in clinical trials.

Systemic Lupus Erythematous Responder Index: Primary Drivers

Systemic Lupus Erythematous Responder Index: Primary Drivers

The efficacy variables with the greatest effect on systemic lupus erythematous (SLE) Responder Index responder status in clinical trials include SLE Disease Activity Index improvement, concomitant medication adherence, and trial completion.

Despite Decline, SLE Mortality Rates Remain Higher Than Non-SLE Mortality Rates

Despite Decline, SLE Mortality Rates Remain Higher Than Non-SLE Mortality Rates

Even though SLE mortality rates are down, they're still higher than non-SLE mortality.

Anti-Ro/SSA-Positive Pregnancies and Fetal Cardiac Conduction Disturbances

Anti-Ro/SSA-Positive Pregnancies and Fetal Cardiac Conduction Disturbances

The recurrence of fetal cardiac conduction disturbances in the fetuses of women expressing anti-Ro/SSA antibodies may be influenced by the season of the year and maternal age.

Impact of Remission, Low Disease Activity on Outcomes in Lupus

Impact of Remission, Low Disease Activity on Outcomes in Lupus

While a treat to target strategy has been proposed for managing SLE, the impact of possible disease outcomes has not been fully evaluated.

Smoking May Be Linked to Pathogenesis of Anti-double Stranded DNA in SLE

Smoking May Be Linked to Pathogenesis of Anti-double Stranded DNA in SLE

Current smoking and >10 pack-years of smoking have demonstrated a strong and specific association with an increased risk for occurrence of anti-double-stranded DNA systemic lupus erythematosus.

In SLE, Medication Non-Adherence, Depression Are Prevalent

In SLE, Medication Non-Adherence, Depression Are Prevalent

In patients with SLE, 62.1% did not adhere to their medication regimens and 35% of patients demonstrated a depressed mood.

Trauma Associated With Incident Systemic Lupus Erythematosus in Women

Trauma Associated With Incident Systemic Lupus Erythematosus in Women

Identification of the biologic pathways by which psychosocial trauma may increase a woman's risk for autoimmune disorders is critical and may offer greater insight into disease etiology and strategies for prevention.

Systemic Lupus Erythematosus-Associated Cognitive Impairment May Be Identified With New Screening Tool

Systemic Lupus Erythematosus-Associated Cognitive Impairment May Be Identified With New Screening Tool

The high prevalence of cognitive impairment in patients with SLE creates a need for a reliable and cost-effective screening tool.

Comprehensive Methods Work to Determine SLE Incidence and Prevalence

Comprehensive Methods Work to Determine SLE Incidence and Prevalence

Research confirmed the increased burden of SLE in black, Asian, and Hispanic women compared with white women.

Hydroxychloroquine Effects on Cholesterol Levels in Systemic Lupus Erythematosus

Hydroxychloroquine Effects on Cholesterol Levels in Systemic Lupus Erythematosus

Research revealed that hydroxychloroquine is associated with reduced LDL-C and total cholesterol levels in patients with lupus.

Patients With SLE at Higher Risk of Developing Metabolic Syndrome

Patients With SLE at Higher Risk of Developing Metabolic Syndrome

More than 25% of SLE patients also have metabolic syndrome.

Complement System a Contributor to Lupus Clinical Manifestations

Complement System a Contributor to Lupus Clinical Manifestations

Mannose-binding lectin of the complement system may contribute to the development of clinical manifestations in SLE.

SHARE Launches Childhood-Onset Systemic Lupus Erythematosus Initiative

SHARE Launches Childhood-Onset Systemic Lupus Erythematosus Initiative

The SHARE initiative established guidelines on cSLE, which is a rare disorder.

Diagnosis and Treatment of Childhood Lupus Nephritis: SHARE Recommendations

Diagnosis and Treatment of Childhood Lupus Nephritis: SHARE Recommendations

The development of lupus nephritis is associated with significant morbidity and mortality.

CVD Prevention Counseling Decreases CVD Risk Factor Prevalence in SLE

CVD Prevention Counseling Decreases CVD Risk Factor Prevalence in SLE

This study finds that a cardiovascular disease prevention counseling program decreases the prevalence of cardiovascular disease risk factors in patients with systemic lupus erythematosus.

B-Cell Depletion Predicts Rituximab Response in Systemic Lupus Erythematosus

B-Cell Depletion Predicts Rituximab Response in Systemic Lupus Erythematosus

Rituximab non-responders may still be amenable to B-cell targeted therapies, such as ofatumumab or obinutuzumab.

No Increased Risk of SLE Found With Current Statin Use

No Increased Risk of SLE Found With Current Statin Use

The risk of developing SLE in current statin users aged ≥40 years was no different than that in nonusers.

Venetoclax Safe, Effective in Women With Systemic Lupus Erythematosus

Venetoclax Safe, Effective in Women With Systemic Lupus Erythematosus

Use of the anti-apoptotic protein B-cell lymphoma 2 inhibitor venetoclax reduced total lymphocyte and disease-relevant B cells in women with SLE.

Sign Up for Free e-newsletters